Akorn-Strides joint venture enters buy agreement with Pfizer for ANDAs Akorn, Inc. , a distinct segment generic pharmaceutical company, today reported that its Akorn-Strides LLC jv has entered into a purchase contract with Pfizer Inc. To sell 16 Abbreviated New Drug Approvals and 6 filed ANDAs online pharmacy . Because of its part, Akorn, Inc. Will receive $35 million in money. Akorn-Strides LLC will continue to manufacture and distribute the accepted products until April 30, 2011.
This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health Information, an unbiased news service editorially, is a scheduled plan of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.